Whitehawk Therapeutics (WHWK) Cash from Operations (2010 - 2026)
Whitehawk Therapeutics (WHWK) reported Cash from Operations of 22208000.0 for Q1 2026, down 87.19% year-over-year from 173339284.21 in Q1 2025, and down 28.86% quarter-over-quarter from 17234000.0 in Q4 2025.
Whitehawk Therapeutics (WHWK) Cash from Operations (2010 - 2026) Analysis & Trends
Whitehawk Therapeutics (WHWK) has 17 years of Cash from Operations data on file, last reported at 22208000.0 in Q1 2026.
- Cash from Operations for Q1 2026 came in at 22208000.0, down 87.19% year-over-year; the trailing twelve-month figure through Mar 2026 was 107777000.0 (down 108.22% YoY), and the FY2025 annual result was 97433000.0, down 63.62% from the prior year.
- Cash from Operations eased to 22208000.0 in Q1 2026 per WHWK's latest filing, from 17234000.0 in the prior quarter.
- Over five years, Cash from Operations peaked at 8195000.0 in Q3 2022 and troughed at 52957000.0 in Q2 2025.
- A 5-year average of 16970235.29 and a median of 15378000.0 in 2025 frame the typical range for Cash from Operations.
- The sharpest annual moves came in 2022 and 2025: Cash from Operations soared 52.83% in 2022, then sank 478.32% in 2025.
- A 5-year view of Cash from Operations shows it stood at 11310000.0 in 2022, then advanced by 14.73% to 9644000.0 in 2023, then tumbled by 56.09% to 15053000.0 in 2024, then retreated by 14.49% to 17234000.0 in 2025, then slipped by 28.86% to 22208000.0 in 2026.
- Business Quant data shows WHWK's Cash from Operations at 22208000.0 in Q1 2026, 17234000.0 in Q4 2025, and 15378000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Ops. (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | -1.67 Mn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | -12.20 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | -2.49 Mn |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 1.43 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | - |
| 10 | Whitehawk Therapeutics | 310.18 Mn | 187.14 Mn | - | -22.21 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -22.21 Mn |
| Mar 31, 2026 | -22.21 Mn |
| Dec 31, 2025 | -17.23 Mn |
| Dec 31, 2025 | -17.23 Mn |
| Sep 30, 2025 | -15.38 Mn |
| Sep 30, 2025 | -15.38 Mn |
| Jun 30, 2025 | -52.96 Mn |
| Jun 30, 2025 | -52.96 Mn |
| Mar 31, 2025 | -11.86 Mn |
| Mar 31, 2025 | -11.86 Mn |
| Dec 31, 2024 | -15.05 Mn |
| Dec 31, 2024 | -15.05 Mn |
| Sep 30, 2024 | -15.69 Mn |
| Sep 30, 2024 | -15.69 Mn |
| Jun 30, 2024 | -9.16 Mn |
| Jun 30, 2024 | -9.16 Mn |
| Mar 31, 2024 | -19.65 Mn |
| Mar 31, 2024 | -19.65 Mn |
| Dec 31, 2023 | -9.64 Mn |
| Dec 31, 2023 | -9.64 Mn |